Objective
to assess 2-year safety and efficacy of Resolute Onyx zotarolimus-eluting stent (ZES), compared with the Orsiro sirolimus-eluting stent (SES) in all comers
Study
prospective, investigator initiated patient and assessor blinded randomised non-inferiority trial
Population
all comers with any coronary syndrome, de novo or restenotic lesions, any lesion length, any reference vessel size, any number or vessels/lesions treated
Endpoints
target vessel failure (TVF), composite of safety (cardiac death or target vessel-related MI) and efficacy (clinically indicated target vessel revascularisation)
Conclusion
at 2-year follow up the rate of target vessel failure was comparable in patients assigned to ZES versus SES
Buiten et al. JACC Cardiovascular Interventions. 2020;13(9);1100-9
